Cancer Research Cancer Research Funding Available  Jordan
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hanna, I. H.
Right arrow Articles by Parl, F. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hanna, I. H.
Right arrow Articles by Parl, F. F.
[Cancer Research 60, 3440-3444, July 1, 2000]
© 2000 American Association for Cancer Research


Biochemistry and Biophysics

Cytochrome P450 1B1 (CYP1B1) Pharmacogenetics: Association of Polymorphisms with Functional Differences in Estrogen Hydroxylation Activity1

Imad H. Hanna, Sheila Dawling, Nady Roodi, F. Peter Guengerich and Fritz F. Parl2

Departments of Biochemistry [I. H. H., F. P. G.] and Pathology[S. D., N. R., F. F. P.], Vanderbilt University Medical Center, Nashville, Tennessee 37232

Activation of 17ß-estradiol (E2) through the formation of catechol estrogen metabolites, 2-OH-E2 and 4-OH-E2, and the C-16{alpha} hydroxylation product, 16{alpha}-OH-E2, has been postulated to be a factor in mammary carcinogenesis. Cytochrome P450 1B1 (CYP1B1) exceeds other P450 enzymes in both estrogen hydroxylation activity and expression level in breast tissue. To determine whether inherited variants of CYP1B1 differ from wild-type CYP1B1 in estrogen hydroxylase activity, we expressed recombinant wild-type and five polymorphic variants of CYP1B1: variant 1 (codon 48Arg->Gly), variant 2 (codon 119Ala->Ser), variant 3 (codon 432Val->Leu), variant 4 (codon453Asn-> Ser), variant 5 (48Gly, 119Ser, 432Leu, 453Ser). The His-tagged proteins were purified by nickel-nitrilotriacetic acid (Ni-NTA) chromatography and analyzed by electrophoresis and spectrophotometry. We performed assays of E2 hydroxylation activity and quantitated production of 2-OH-E2, 4-OH-E2, and 16{alpha}-OH-E2 by gas chromatography/mass spectrometry. Wild-type CYP1B1 formed 4-OH-E2 as main product (Km, 40 ± 8 µM; kcat 4.4 ± 0.4, min-1; kcat/Km, 110 mM-1min-1), followed by 2-OH-E2 (Km, 34 ± 4 µM; kcat, 1.9 ± 0.1 min-1; kcat/Km, 55 mM-1min-1) and 16{alpha}-OH-E2 (Km, 39 ± 5.7 µM; kcat, 0.30 ± 0.02 min-1; kcat/Km, 7.6 mM-1min-1). The CYP1B1 variants also formed 4-OH-E2 as the main product but displayed 2.4- to 3.4-fold higher catalytic efficiencies kcat/Km than the wild-type enzyme, ranging from 270 mM-1min-1 for variant 4, to 370 mM-1min-1 for variant 2. The variant enzymes also exceeded wild-type CYP1B1 with respect to 2- and 16{alpha}-hydroxylation activity. Thus, inherited alterations in CYP1B1 estrogen hydroxylation activity may be associated with significant changes in estrogen metabolism and, thereby, may possibly explain interindividual differences in breast cancer risk associated with estrogen-mediated carcinogenicity.




This article has been cited by other articles:


Home page
CarcinogenesisHome page
M. N. Timofeeva, S. Kropp, W. Sauter, L. Beckmann, A. Rosenberger, T. Illig, B. Jager, K. Mittelstrass, H. Dienemann, The LUCY-Consortium, et al.
CYP450 polymorphisms as risk factors for early-onset lung cancer: gender-specific differences
Carcinogenesis, July 1, 2009; 30(7): 1161 - 1169.
[Abstract] [Full Text] [PDF]


Home page
Anticancer ResHome page
L. FONTANA, L. DELORT, L. JOUMARD, N. RABIAU, R. BOSVIEL, S. SATIH, L. GUY, J.-P. BOITEUX, Y.-J. BIGNON, A. CHAMOUX, et al.
Genetic Polymorphisms in CYP1A1, CYP1B1, COMT, GSTP1 and NAT2 Genes and Association with Bladder Cancer Risk in a French Cohort
Anticancer Res, May 1, 2009; 29(5): 1631 - 1635.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
M. L. Cote, W. Yoo, A. S. Wenzlaff, G. M. Prysak, S. K. Santer, G. B. Claeys, A. L. Van Dyke, S. J. Land, and A. G. Schwartz
Tobacco and estrogen metabolic polymorphisms and risk of non-small cell lung cancer in women
Carcinogenesis, April 1, 2009; 30(4): 626 - 635.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
J. Beuten, J. A.L. Gelfond, J. J. Byrne, I. Balic, A. C. Crandall, T. L. Johnson-Pais, I. M. Thompson, D. K. Price, and R. J. Leach
CYP1B1 variants are associated with prostate cancer in non-Hispanic and Hispanic Caucasians
Carcinogenesis, September 1, 2008; 29(9): 1751 - 1757.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
B. Diergaarde, J. D. Potter, E. R. Jupe, S. Manjeshwar, C. D. Shimasaki, T. W. Pugh, D. C. DeFreese, B. A. Gramling, I. Evans, and E. White
Polymorphisms in Genes Involved in Sex Hormone Metabolism, Estrogen Plus Progestin Hormone Therapy Use, and Risk of Postmenopausal Breast Cancer
Cancer Epidemiol. Biomarkers Prev., July 1, 2008; 17(7): 1751 - 1759.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
S. Zienolddiny, D. Campa, H. Lind, D. Ryberg, V. Skaug, L. B. Stangeland, F. Canzian, and A. Haugen
A comprehensive analysis of phase I and phase II metabolism gene polymorphisms and risk of non-small cell lung cancer in smokers
Carcinogenesis, June 1, 2008; 29(6): 1164 - 1169.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
T. M. Sissung, R. Danesi, D. K. Price, S. M. Steinberg, R. de Wit, M. Zahid, N. Gaikwad, E. Cavalieri, W. L. Dahut, D. L. Sackett, et al.
Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel
Mol. Cancer Ther., January 1, 2008; 7(1): 19 - 26.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
P Vineis, F Veglia, S Garte, C Malaveille, G Matullo, A Dunning, M Peluso, L Airoldi, K Overvad, O Raaschou-Nielsen, et al.
Genetic susceptibility according to three metabolic pathways in cancers of the lung and bladder and in myeloid leukemias in nonsmokers
Ann. Onc., July 1, 2007; 18(7): 1230 - 1242.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
S. K. Holt, M. A. Rossing, K. E. Malone, S. M. Schwartz, N. S. Weiss, and C. Chen
Ovarian Cancer Risk and Polymorphisms Involved in Estrogen Catabolism
Cancer Epidemiol. Biomarkers Prev., March 1, 2007; 16(3): 481 - 489.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. R. Belous, D. L. Hachey, S. Dawling, N. Roodi, and F. F. Parl
Cytochrome P450 1B1-Mediated Estrogen Metabolism Results in Estrogen-Deoxyribonucleoside Adduct Formation
Cancer Res., January 15, 2007; 67(2): 812 - 817.
[Abstract] [Full Text] [PDF]


Home page
Am J EpidemiolHome page
V. Paracchini, S. Raimondi, I. T. Gram, D. Kang, N. A. Kocabas, V. N. Kristensen, D. Li, F. F. Parl, T. Rylander-Rudqvist, P. Soucek, et al.
Meta- and Pooled Analyses of the Cytochrome P-450 1B1 Val432Leu Polymorphism and Breast Cancer: A HuGE-GSEC Review
Am. J. Epidemiol., January 15, 2007; 165(2): 115 - 125.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
Y. Tanaka, H. Hirata, Z. Chen, N. Kikuno, K. Kawamoto, S. Majid, T. Tokizane, S. Urakami, H. Shiina, K. Nakajima, et al.
Polymorphisms of Catechol-O-Methyltransferase in Men with Renal Cell Cancer
Cancer Epidemiol. Biomarkers Prev., January 1, 2007; 16(1): 92 - 97.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
S. I. Berndt, N. Chatterjee, W.-Y. Huang, S. J. Chanock, R. Welch, E. D. Crawford, and R. B. Hayes
Variant in Sex Hormone-Binding Globulin Gene and the Risk of Prostate Cancer
Cancer Epidemiol. Biomarkers Prev., January 1, 2007; 16(1): 165 - 168.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
M. H. Tao, Q. Cai, W. H. Xu, N. Kataoka, W. Wen, W. Zheng, Y. B. Xiang, Z.-F. Zhang, and X. O. Shu
Cytochrome P450 1B1 and Catechol-O-Methyltransferase Genetic Polymorphisms and Endometrial Cancer Risk in Chinese Women
Cancer Epidemiol. Biomarkers Prev., December 1, 2006; 15(12): 2570 - 2573.
[Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
P. S. Crooke, M. D. Ritchie, D. L. Hachey, S. Dawling, N. Roodi, and F. F. Parl
Estrogens, enzyme variants, and breast cancer: a risk model.
Cancer Epidemiol. Biomarkers Prev., September 1, 2006; 15(9): 1620 - 1629.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
T. M. Sissung, D. K. Price, A. Sparreboom, and W. D. Figg
Pharmacogenetics and Regulation of Human Cytochrome P450 1B1: Implications in Hormone-Mediated Tumor Metabolism and a Novel Target for Therapeutic Intervention
Mol. Cancer Res., March 1, 2006; 4(3): 135 - 150.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. Thibaudeau, J. Lepine, J. Tojcic, Y. Duguay, G. Pelletier, M. Plante, J. Brisson, B. Tetu, S. Jacob, L. Perusse, et al.
Characterization of Common UGT1A8, UGT1A9, and UGT2B7 Variants with Different Capacities to Inactivate Mutagenic 4-Hydroxylated Metabolites of Estradiol and Estrone
Cancer Res., January 1, 2006; 66(1): 125 - 133.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
T. A. Sellers, J. M. Schildkraut, V. S. Pankratz, R. A. Vierkant, Z. S. Fredericksen, J. E. Olson, J. Cunningham, W. Taylor, M. Liebow, C. McPherson, et al.
Estrogen Bioactivation, Genetic Polymorphisms, and Ovarian Cancer
Cancer Epidemiol. Biomarkers Prev., November 1, 2005; 14(11): 2536 - 2543.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
J. R. Starr, C. Chen, D. R. Doody, L. Hsu, S. Ricks, N. S. Weiss, and S. M. Schwartz
Risk of Testicular Germ Cell Cancer in Relation to Variation in Maternal and Offspring Cytochrome P450 Genes Involved in Catechol Estrogen Metabolism
Cancer Epidemiol. Biomarkers Prev., September 1, 2005; 14(9): 2183 - 2190.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
A. DeMichele, R. Aplenc, J. Botbyl, T. Colligan, L. Wray, M. Klein-Cabral, A. Foulkes, P. Gimotty, J. Glick, B. Weber, et al.
Drug-Metabolizing Enzyme Polymorphisms Predict Clinical Outcome in a Node-Positive Breast Cancer Cohort
J. Clin. Oncol., August 20, 2005; 23(24): 5552 - 5559.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
G. Li, Z. Liu, E. M. Sturgis, R. M. Chamberlain, M. R. Spitz, and Q. Wei
CYP2E1 G1532C, NQO1 Pro187Ser, and CYP1B1 Val432Leu Polymorphisms Are Not Associated with Risk of Squamous Cell Carcinoma of the Head and Neck
Cancer Epidemiol. Biomarkers Prev., April 1, 2005; 14(4): 1034 - 1036.
[Full Text] [PDF]


Home page
Cancer Res.Home page
P. Kisselev, W.-H. Schunck, I. Roots, and D. Schwarz
Association of CYP1A1 Polymorphisms with Differential Metabolic Activation of 17{beta}-Estradiol and Estrone
Cancer Res., April 1, 2005; 65(7): 2972 - 2978.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
W. Wen, Q. Cai, X.-O. Shu, J.-R. Cheng, F. Parl, L. Pierce, Y.-T. Gao, and W. Zheng
Cytochrome P450 1B1 and Catechol-O-Methyltransferase Genetic Polymorphisms and Breast Cancer Risk in Chinese Women: Results from the Shanghai Breast Cancer Study and a Meta-analysis
Cancer Epidemiol. Biomarkers Prev., February 1, 2005; 14(2): 329 - 335.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
J. A. Doherty, N. S. Weiss, R. J. Freeman, D. A. Dightman, P. J. Thornton, J. R. Houck, L. F. Voigt, M. A. Rossing, S. M. Schwartz, and C. Chen
Genetic Factors in Catechol Estrogen Metabolism in Relation to the Risk of Endometrial Cancer
Cancer Epidemiol. Biomarkers Prev., February 1, 2005; 14(2): 357 - 366.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
S. Bandiera, S. Weidlich, V. Harth, P. Broede, Y. Ko, and T. Friedberg
Proteasomal Degradation of Human CYP1B1: Effect of the Asn453Ser Polymorphism on the Post-Translational Regulation of CYP1B1 Expression
Mol. Pharmacol., February 1, 2005; 67(2): 435 - 443.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
J. L. Port, K. Yamaguchi, B. Du, M. De Lorenzo, M. Chang, P. M. Heerdt, L. Kopelovich, C. B. Marcus, N. K. Altorki, K. Subbaramaiah, et al.
Tobacco smoke induces CYP1B1 in the aerodigestive tract
Carcinogenesis, November 1, 2004; 25(11): 2275 - 2281.
[Abstract] [Full Text] [PDF]


Home page
Mol Hum ReprodHome page
Y. Saijo, F. Sata, H. Yamada, K. Suzuki, S. Sasaki, T. Kondo, Y.Y. Gong, E.H. Kato, S. Shimada, M. Morikawa, et al.
Ah receptor, CYP1A1, CYP1A2 and CYP1B1 gene polymorphisms are not involved in the risk of recurrent pregnancy loss
Mol. Hum. Reprod., October 1, 2004; 10(10): 729 - 733.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
T. Rylander-Rudqvist, S. Wedren, G. Jonasdottir, S. Ahlberg, E. Weiderpass, I. Persson, and M. Ingelman-Sundberg
Cytochrome P450 1B1 Gene Polymorphisms and Postmenopausal Endometrial Cancer Risk
Cancer Epidemiol. Biomarkers Prev., September 1, 2004; 13(9): 1515 - 1520.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
M. McGrath, S. E. Hankinson, L. Arbeitman, G. A. Colditz, D. J. Hunter, and I. De Vivo
Cytochrome P450 1B1 and catechol-O-methyltransferase polymorphisms and endometrial cancer susceptibility
Carcinogenesis, April 1, 2004; 25(4): 559 - 565.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. Sasaki, Y. Tanaka, S. T. Okino, M. Nomoto, S. Yonezawa, M. Nakagawa, S. Fujimoto, N. Sakuragi, and R. Dahiya
Polymorphisms of the CYP1B1 Gene as Risk Factors for Human Renal Cell Cancer
Clin. Cancer Res., March 15, 2004; 10(6): 2015 - 2019.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
S. S. Tworoger, J. Chubak, E. J. Aiello, C. M. Ulrich, C. Atkinson, J. D. Potter, Y. Yasui, P. L. Stapleton, J. W. Lampe, F. M. Farin, et al.
Association of CYP17, CYP19, CYP1B1, and COMT Polymorphisms with Serum and Urinary Sex Hormone Concentrations in Postmenopausal Women
Cancer Epidemiol. Biomarkers Prev., January 1, 2004; 13(1): 94 - 101.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
D. L. Hachey, S. Dawling, N. Roodi, and F. F. Parl
Sequential Action of Phase I and II Enzymes Cytochrome P450 1B1 and Glutathione S-Transferase P1 in Mammary Estrogen Metabolism
Cancer Res., December 1, 2003; 63(23): 8492 - 8499.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
T. Rylander-Rudqvist, S. Wedren, F. Granath, K. Humphreys, S. Ahlberg, E. Weiderpass, M. Oscarson, M. Ingelman-Sundberg, and I. Persson
Cytochrome P450 1B1 gene polymorphisms and postmenopausal breast cancer risk
Carcinogenesis, September 1, 2003; 24(9): 1533 - 1539.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. Sasaki, Y. Tanaka, M. Kaneuchi, N. Sakuragi, and R. Dahiya
CYP1B1 Gene Polymorphisms Have Higher Risk for Endometrial Cancer, and Positive Correlations with Estrogen Receptor {alpha} and Estrogen Receptor {beta} Expressions
Cancer Res., July 15, 2003; 63(14): 3913 - 3918.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
J. S. Mammen, G. S. Pittman, Y. Li, F. Abou-Zahr, B. A. Bejjani, D. A. Bell, P. T. Strickland, and T. R. Sutter
Single amino acid mutations, but not common polymorphisms, decrease the activity of CYP1B1 against (-)benzo[a]pyrene-7R-trans-7,8-dihydrodiol
Carcinogenesis, July 1, 2003; 24(7): 1247 - 1255.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Dawling, N. Roodi, and F. F. Parl
Methoxyestrogens Exert Feedback Inhibition on Cytochrome P450 1A1 and 1B1
Cancer Res., June 15, 2003; 63(12): 3127 - 3132.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
M. Yang, J.-Y. Jang, S. Kim, S.-M. Lee, S.-S. Chang, H.-K. Cheong, E. Lee, D. Kang, H. Kim, T. Kawamoto, et al.
Genetic effects on urinary 1-hydroxypyrene levels in a Korean population
Carcinogenesis, June 1, 2003; 24(6): 1085 - 1089.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
L. C. Hodges, J. D. Cook, E. K. Lobenhofer, L. Li, L. Bennett, P. R. Bushel, C. M. Aldaz, C. A. Afshari, and C. L. Walker
Tamoxifen Functions As a Molecular Agonist Inducing Cell Cycle-Associated Genes in Breast Cancer Cells
Mol. Cancer Res., February 1, 2003; 1(4): 300 - 311.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
B. Bournique and A. Lemarie
Docetaxel (Taxotere) Is Not Metabolized by Recombinant Human CYP1B1 in Vitro, but Acts as an Effector of This Isozyme.
Drug Metab. Dispos., November 1, 2002; 30(11): 1149 - 1152.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
I. De Vivo, S. E. Hankinson, L. Li, G. A. Colditz, and D. J. Hunter
Association of CYP1B1 Polymorphisms and Breast Cancer Risk
Cancer Epidemiol. Biomarkers Prev., May 1, 2002; 11(5): 489 - 492.
[Abstract] [Full Text] [PDF]


Home page
J. Med. Genet.Home page
M M de Jong, I M Nolte, G J te Meerman, W T A van der Graaf, J C Oosterwijk, J H Kleibeuker, M Schaapveld, and E G E de Vries
Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility
J. Med. Genet., April 1, 2002; 39(4): 225 - 242.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
E. Aklillu, M. Oscarson, M. Hidestrand, B. Leidvik, C. Otter, and M. Ingelman-Sundberg
Functional Analysis of Six Different Polymorphic CYP1B1 Enzyme Variants Found in an Ethiopian Population
Mol. Pharmacol., March 1, 2002; 61(3): 586 - 594.
[Abstract] [Full Text] [PDF]


Home page
Toxicol SciHome page
S. A. Larsen-Su and D. E. Williams
Transplacental Exposure to Indole-3-carbinol Induces Sex-Specific Expression of CYP1A1 and CYP1B1 in the Liver of Fischer 344 Neonatal Rats
Toxicol. Sci., December 1, 2001; 64(2): 162 - 168.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Y.-J. Chun, S. Kim, D. Kim, S.-K. Lee, and F. P. Guengerich
A New Selective and Potent Inhibitor of Human Cytochrome P450 1B1 and Its Application to Antimutagenesis
Cancer Res., November 1, 2001; 61(22): 8164 - 8170.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Dawling, N. Roodi, R. L. Mernaugh, X. Wang, and F. F. Parl
Catechol-O-Methyltransferase (COMT)-mediated Metabolism of Catechol Estrogens: Comparison of Wild-Type and Variant COMT Isoforms
Cancer Res., September 1, 2001; 61(18): 6716 - 6722.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Y. Ko, J. Abel, V. Harth, P. Brode, C. Antony, S. Donat, H.-P. Fischer, M. E. Ortiz-Pallardo, R. Thier, A. Sachinidis, et al.
Association of CYP1B1 Codon 432 Mutant Allele in Head and Neck Squamous Cell Cancer Is Reflected by Somatic Mutations of p53 in Tumor Tissue
Cancer Res., June 1, 2001; 61(11): 4398 - 4404.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
G. Garcia-Cardena, J. Comander, K. R. Anderson, B. R. Blackman, and M. A. Gimbrone Jr.
Inaugural Article: Biomechanical activation of vascular endothelium as a determinant of its functional phenotype
PNAS, April 10, 2001; 98(8): 4478 - 4485.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2000 by the American Association for Cancer Research.